ATHE
Alterity Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · AU
$2.43
−7.25%Next report
Analyst consensus
- Next report date
- Mar 4, 2027
- EPS estimate
- -$0.03
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 28, 2026
- EPS actual
- -$0.05
- EPS estimate
- -$0.12
- Revenue actual
- $289.0K
- Revenue estimate
- $2.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +64.8%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $11
- PT range
- $10 – $12
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 28, 2026 | -$0.12 | -$0.05 | Beat 56.02% | $289.0K |
| Aug 28, 2025 | -$0.43 | -$0.40 | Beat 7.21% | $3.8M |
| Feb 27, 2025 | -$0.53 | -$0.00 | Beat 99.87% | $803.0K |
| Aug 28, 2024 | -$0.05 | -$0.00 | Beat 96.21% | $2.1M |
| Apr 11, 2024 | — | -$0.00 | — | $1.1M |
| Feb 28, 2024 | -$0.11 | -$0.00 | Beat 97.53% | $1.9M |
| Mar 31, 2023 | -$0.12 | -$0.00 | Beat 99.01% | $765.2K |
| Aug 30, 2022 | -$1.97 | -$1.43 | Beat 27.48% | $1.8M |
| Feb 27, 2022 | — | -$0.98 | — | $980 |
| Jun 30, 2020 | — | -$0.01 | — | -$1.9M |
| Dec 31, 2019 | — | -$0.01 | — | $1.9M |
| Jun 30, 2019 | — | -$0.01 | — | $2.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 4, 2027